Editor’s Note: Related tickers: Infosys Ltd ADR (NYSE:INFY), Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), Marathon Petroleum Corp (NYSE:MPC), VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), BHP Billiton Limited (ADR) (NYSE:BHP), Tesoro Corporation (NYSE:TSO)
Top dog
The largest equity position in terms of value is in Infosys Ltd ADR (NYSE:INFY), where the hedge fund holds a $95 million stake, consisting of 1,762,750 shares. Polaris was bullish on the company in Q1, raising the holding from 1.6 million shares worth $68.6 million reported at the end of December. The IT consulting and technology company has had an up and down 2013, with shares plummeting 20% on April 12th following a disappointing fourth quarter and below-average FY2013 guidance. The company expects its revenue to grow by 6-10% over the current fiscal year, missing the 12% rate forecasted by analysts, and even worse, the sell-side expects EPS to be stagnant this year.
It’s possible that Horn and Polaris are still bullish on Infosys Ltd ADR (NYSE:INFY), as it trades at attractive multiples—14 times forward earnings and a 0.98 PEG—but one could argue that these metrics are meaningless in a period of declining growth. The IT consulting marketplace as a whole doesn’t looking mind-blowingly attractive, with the S&P citing “a hazy outlook for the global economy” as a key reason why companies like Infosys Ltd ADR (NYSE:INFY) don’t face the best of prospects moving forward. Thus, it’s also quite possible that Horn and Polaris have been stung by the IT consulting industry bellwether’s fall from grace, much like most Infosys investors. Overall, we’d be cautious.
Teva
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is also held by Polaris and is worth $88.1 million, up from $65.4 million disclosed at the end of 2012. The quantity of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shares in the holding advanced to 2,220,053 shares, from 1,751,753 at the close of the prior quarter, and the stock sports a forward P/E of 7.2x and a year-to-date return of above 7%; unlike Infosys, there’s quite a bit to like about Teva’s for 2014 and beyond.
While mainstream companies like VIVUS, Inc. (NASDAQ:VVUS) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) get most of the hype in the pharma space, Teva’s footprint in the generic drug marketplace should not be overlooked. In the same economic rationale as generic foods becoming more popular post-recession, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)’s generics have seen increased demand in the past few years. What’s more, the company’s staple of proprietary products—multiple sclerosis drug Copaxone, the duo of Provigil and Nuvigil for sleep disorders, and Parkinson’s drug Azilect, to name a few—are key strengths.
From a valuation standpoint, shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) trade at a ridiculously low 7 times forward earnings, and while EPS did shrink by an average of 1% annually over the past half-decade, future growth is expected to pick up. Wall Street forecasts Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) will expand its bottom line by 7.1% a year through 2017, and if higher-margin products like Copaxone can see extended shelf life post-patent via changes in dosage requirements, there is upside to this figure.
Marathon Petroleum
The hedge fund also reported ownership of 910,791 shares of Marathon Petroleum Corp (NYSE:MPC), down from 939,391 shares reported in the previous filing. The value of the stake increased to $81.6 million, from $59.2 million, however, as shares of the oil and gas refiner & marketer have returned more than 25% year-to-date. Marathon Petroleum Corp (NYSE:MPC) is still trading at a forward P/E of 7.4x, and we’ll be watching its plans to spend $300 million to augment refining capacity in two facilities in Ohio’s Utica shale.
Marathon Petroleum Corp (NYSE:MPC) also has refineries in East Texas, Louisiana, Illinois, Kentucky and Detroit, Michigan. Aside from being a bet on domestic energy—something we’ve seen a lot of lately in the hedge fund industry—Horn and Polaris’ play in Marathon Petroleum Corp (NYSE:MPC) specifically indicates their willingness to dig deep into the value bin. Some investors may prefer E&P companies, or even the barges that ship oil down to LNG export facilities, but on the whole, Marathon offers a bargain that literally can’t be beat.
The company’s stock sports the fifth lowest year-ahead earnings multiple of its peers in the refining industry, and its price-to-sales multiple is at a whopping 70% below parity. A PEG near 0.70 also indicates that Mr. Market doesn’t believe the sell-side’s earnings forecast of 11% annual growth over the next five years, which is below peers like Tesoro Corporation (NYSE:TSO) and Eagle Rock. Needless to say, if Marathon Petroleum Corp (NYSE:MPC) can prosper in the Utica shale while holding steady in the rest of its operations, this discount should be erased sooner rather than later. It’s easy to see why Polaris is bullish.
Best of the rest
Polaris disclosed a $68 million stakein BHP Billiton Limited (ADR) (NYSE:BHP), totalling 1,171,049 shares. In the previous filing, the hedge fund reported holding 1,034,749 shares, worth $72.8 million. Carter’sis the last in our top five list, with the fund holding a $64.6 million position. The number ofshares held by the fund remains unchanged from the end of last year at 1,127,851 shares. The previous value of the holding was $62.8 million.
Final thoughts
It appears that Polaris is loaded up on each of its top holdings for very different reasons. From Infosys Ltd ADR (NYSE:INFY)’s position as IT’s falling knife to Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)’s desirable mix of generic and patent-protected drugs, there are plenty of reasons to pay attention. Don’t forget about energy play Marathon Petroleum Corp (NYSE:MPC) too, as there’s a potential for a massive value-based appreciation in the coming months. Learn why you should track hedge fund sentiment.
Disclosure: none